Hjem › Glioblastom › Illinois
Glioblastom kliniske forsøg i Illinois
16 studier for Glioblastom søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- University of Chicago Comprehensive Cancer Center, Chicago
- University of Chicago Medicine-Orland Park, Orland Park
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT05432804Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Northwestern University, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT05902169A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
- Northwestern Univerity, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05303467A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Northwestern Memorial Hospital, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT05765812Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- Alton Memorial Hospital, Alton
- Decatur Memorial Hospital, Decatur
- Northwestern Medicine Cancer Center Kishwaukee, DeKalb
- og 5 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT07452458Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
- Northwestern University, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06410248Targeted Pediatric High-Grade Glioma Therapy
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererObservationsstudie
12 Months – 39 Years · Alle køn · Opdateret 8. sep. 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 2
Alder 12 til 39 · Alle køn · Opdateret 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- Northwestern Medicine, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07464925WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
- Northwestern University, Chicago
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT05879250Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererTidlig fase 1Frivillige med god helbredstilstand velkomne
Alder 1 til 21 · Alle køn · Opdateret 29. jun. 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 2
12 Months – 39 Years · Alle køn · Opdateret 29. maj 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Northwestern Memorial Hospital, Chicago
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT06810544SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.